Management of refractory ascites
- PMID: 21192246
- DOI: 10.1097/MJT.0b013e3181ff7a8b
Management of refractory ascites
Abstract
Ascites that does not respond or recurs after high-dose diuresis and sodium restriction should be considered refractory ascites. As cirrhosis advances, the escaping fluid overwhelms the lymphatic return. Decrease in renal plasma flow leads to increased sodium reabsorption at the proximal tubule leading to decreased responsiveness to loop diuretics and mineralocorticoid antagonists, which work distally. These complex hemodynamic alterations lead to refractory ascites. In refractory ascites, high-dose diuresis (400 mg of spironolactone and 160 mg of furosemide) and sodium restriction (<90 mmol/d) result in inadequate weight loss and sub optimal sodium excretion (<78 mmol/d). Further use of diuretics is limited by complications such as encephalopathy, azotemia, renal insufficiency, hyponatremia, and hyperkalemia. Therapy for refractory ascites is limited. The available therapies are repeated large volume paracentesis (LVP), transjugular intrahepatic portosystemic shunts, peritoneovenous shunts, investigational medical therapies, and liver transplantation. LVP with concomitant volume expanders is the initial treatment of choice. Transjugular intrahepatic portosystemic seems to be superior to LVP in reducing the need for repeated paracentesis and improves the quality of life. Several treatments that act at different steps in the pathogenesis of ascites are investigational, and some show promising results. Splanchnic and peripheral vasoconstrictors (Octreotide, Midodrine, and Terlipressin) increase effective arterial volume and decrease activation of the renin-angiotensin system with resultant increase in renal sodium excretion. Clonidine when given with spironolactone has been shown to cause rapid mobilization of ascites by significantly decreasing the sympathetic activity and renin-aldosterone levels. Natural aquaretics and synthetic V2 receptor antagonists (satavaptan) are being evaluated for mobilization of ascites by increasing the excretion of solute-free water. Liver transplantation remains the only definitive therapy for refractory ascites. Because refractory ascites is a poor prognostic sign, liver transplantation should be considered and incorporated early in the treatment plan.
Similar articles
-
[New therapeutic paradigm and concepts for patients with cirrhotic refractory ascites].Zhonghua Gan Zang Bing Za Zhi. 2017 Apr 20;25(4):249-253. doi: 10.3760/cma.j.issn.1007-3418.2017.04.003. Zhonghua Gan Zang Bing Za Zhi. 2017. PMID: 28494541 Chinese.
-
Management of ascites and hepatorenal syndrome.Hepatol Int. 2018 Feb;12(Suppl 1):122-134. doi: 10.1007/s12072-017-9815-0. Epub 2017 Aug 23. Hepatol Int. 2018. PMID: 28836115 Review.
-
Treatment of ascites in cirrhosis. Diuretics, peritoneovenous shunt, and large-volume paracentesis.Gastroenterol Clin North Am. 1992 Mar;21(1):237-56. Gastroenterol Clin North Am. 1992. PMID: 1568775 Review.
-
Pathophysiology, diagnosis and treatment of ascites in cirrhosis.Ann Hepatol. 2002 Apr-Jun;1(2):72-9. Ann Hepatol. 2002. PMID: 15115971 Review.
-
ePTFE-TIPS vs repetitive LVP plus albumin for the treatment of refractory ascites in patients with cirrhosis.Liver Int. 2018 Jun;38(6):1036-1044. doi: 10.1111/liv.13615. Epub 2018 Jan 15. Liver Int. 2018. PMID: 29091351
Cited by
-
The Palliative Management of Refractory Cirrhotic Ascites Using the PleurX (©) Catheter.Can J Gastroenterol Hepatol. 2016;2016:4680543. doi: 10.1155/2016/4680543. Epub 2016 Jun 5. Can J Gastroenterol Hepatol. 2016. PMID: 27446840 Free PMC article.
-
Efficacy of tolvaptan for the patients with advanced hepatocellular carcinoma.World J Gastroenterol. 2017 Aug 7;23(29):5379-5385. doi: 10.3748/wjg.v23.i29.5379. World J Gastroenterol. 2017. PMID: 28839438 Free PMC article.
-
Ascites in patients with cirrhosis.Can Fam Physician. 2013 Dec;59(12):1297-9; e538-40. Can Fam Physician. 2013. PMID: 24336542 Free PMC article. No abstract available.
-
Clinical efficacy of tolvaptan for treatment of refractory ascites in liver cirrhosis patients.World J Gastroenterol. 2014 Aug 28;20(32):11400-5. doi: 10.3748/wjg.v20.i32.11400. World J Gastroenterol. 2014. PMID: 25170228 Free PMC article.
-
Ascites, refractory ascites and hyponatremia in cirrhosis.Gastroenterol Rep (Oxf). 2017 May;5(2):104-112. doi: 10.1093/gastro/gox010. Epub 2017 Apr 24. Gastroenterol Rep (Oxf). 2017. PMID: 28533908 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials